VTT Technical Research Centre of Finland has
started a large European project, combining
the forces of European research institutes
and companies for developing the next
generation of biofuel. The NEMO project,
which has received funding of EUR 5.9
million from the EU, is aimed at developing
manufacturing methods for liquid biofuel
from agricultural and forestry waste, such
as straws and wood chips.
 |
15.9.2009  |
|
VTT Newsletter 05 | 2009 |
|
|
Dear recipient, VTT´s electronic newsletter has been revised. It consists of the latest news releases concerning research, science, technology and business applications. In addition to these, we inform you about the newest publications and other current topics. The links will take you to VTT's website.
You can subscribe to or unsubscribe from the list in address: http://www.vtt.fi/newsletter_subscribe.htm |
|
|
| Science - impact - potential of technology | |
|
|
|
VTT launches large European cooperation project for developing manufacturing method for biofuel |
|
|
|
|
|
|
|
 |
|
|
|
|
|
Researchers of VTT, the University of Turku and the University of Heidelberg discover new information on spreading of cancer
|
|
|
|
|
|
A joint research
group of VTT
Technical Research
Centre of Finland
and the University
of Turku, led by
Professor Johanna
Ivaska, has
discovered a
mechanism lung
cancer cells use
when spreading into
the body to form
metastases. The
study has been
published in Science
Signaling on 30th
June 2009. In
cooperation with the
University of
Heidelberg, they
have also found a
factor controlling
the spreading of
several different
cancer types. The
common feature in
both findings is
that they explain
the lethal ability
of cancer cells to
“start running” and
spread from the
original tumour to
other parts of the
body.
|
|
|
|
|
|
|
|
| Business from technology - applications | |
|
|
|
|
VTT starts to investigate Bayer Schering Pharma’s preclinical anti-cancer compounds |
|
|
|
|
|
VTT Technical Research Centre of Finland and
Bayer Schering Pharma AG, Germany have
signed a two-year research contract to study
the mode of action of a Bayer Schering
Pharma’s preclinical cancer drugs. As part
of this contract, VTT will use its new gene
and cancer biology methods such as the
3D-cell culture model developed at VTT’s
Medical Biotechnology unit in Turku,
Finland.
|
|
|
|
|
|
|
|
| Other topical | |
|
|
|
New publications
Innovation Excellence Master Class, 27-29 October, 2009 |
|
| Copyright VTT 2009 • Address: P.O. Box 1000, FI-02044 VTT • Tel: +358 20 722 111 • Fax: +358 20 722 7001 • info@vtt.fi | |